NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

Now look at the recurrent GBM data.

Sigh

Yes RK, look again at the recurrent GBM data.

You have been mislead.

The recurrent GBM data in that paper you use as a source is reported from the time of "initial surgical diagnosis of glioblastoma".

So, for example, Your Patient 16 (Patient 10-1) where you report: "28.93 OS"

Guess what?

His OS from recurrence was only 13.1 months. So, as far as cross-over goes, a patient like 10-1 would be expected to live an additional 13.1 months after x-over, not an additional 29 months.

Similarly:
Patient 1-4 10.8 months
Patient 1-7 7.3 months
Patient 1-8 44 months
Patient 5-2 11.6 months
Patient 5-6 15.1 months
Patient 10-7 11 months
Patient 10-8 7.1 months

The median is 11.2 months for the rGBM in that trial. (the median for the rapid progressors in the info arm was 15.3 months - more evidence psPD have been included in the Info ARM.)

If "Everyone is living longer" why didn't these DCVax treated patients live longer? 11.2 month median for rGBM in the Ph1 trial. What does the info arm poster say the median OS is for recurrent patients? It says 8.3 to 10.8. So it squeaks outside that but remember ALL these Ph1 patients qualified for repeat surgery - (that's how they made the DCVax).

Isnt it interesting to note that only 1 rGBM patient (out of 8) treated with DCVax in the earlier UCLA trial lived beyond that 15.3 months reported for the Info Arm?


Buried deep within a supplemental appendix is the data you need to use to make correct rGBM comparisons.

Let the data speak to you and read it w/o bias. It will help you discern hype from substance.



I'll have more to say about our other conversation later but thanks for your clarifying response there.